Latest Lung Cancer News | NSCLC/SCLC Treatment Information

Lung Cancers News

LUNG CANCER ADVISOR

Lung Cancers News

PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.

Phase 2 Trial to Evaluate Osimertinib in EGFR TKI-Resistant NSCLC

A multicenter, phase 2 trial will assess the efficacy and safety of osimertinib among patients with isolated CNS or systemic progression of EGFR mutation-positive non-small cell lung cancer after treatment with an EGFR tyrosine kinase inhibitor.
Experts acknowledged the growing importance of genomics to the field, but said more research is needed to justify changing current practices.

KRAS-Mutant NSCLC in a Nation-Wide Prospective Cohort

The CRISP registry is a nationwide, prospective, observational cohort that was developed to characterize the treatment of patients with KRAS-mutant non-small cell lung cancer before and after the likely future approval of KRAS inhibitors.
Next post in Lung Cancer News